Bridgefront Capital LLC bought a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 20,512 shares of the company’s stock, valued at approximately $222,000.
Several other institutional investors have also recently made changes to their positions in ALLO. Capital Impact Advisors LLC grew its holdings in Allogene Therapeutics by 24.5% during the 3rd quarter. Capital Impact Advisors LLC now owns 19,539 shares of the company’s stock valued at $196,000 after purchasing an additional 3,839 shares during the last quarter. Balyasny Asset Management LLC purchased a new stake in shares of Allogene Therapeutics in the third quarter worth approximately $448,000. BNP Paribas Arbitrage SNC lifted its stake in shares of Allogene Therapeutics by 816.8% during the 3rd quarter. BNP Paribas Arbitrage SNC now owns 288,390 shares of the company’s stock worth $3,115,000 after acquiring an additional 256,934 shares during the last quarter. State Street Corp boosted its holdings in Allogene Therapeutics by 18.1% during the 3rd quarter. State Street Corp now owns 6,680,297 shares of the company’s stock valued at $72,147,000 after acquiring an additional 1,025,973 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new position in Allogene Therapeutics in the 3rd quarter valued at $561,000. Institutional investors own 72.94% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on ALLO shares. Oppenheimer lowered their target price on shares of Allogene Therapeutics from $32.00 to $28.00 and set an “outperform” rating for the company in a research note on Wednesday, March 1st. The Goldman Sachs Group dropped their target price on shares of Allogene Therapeutics from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Wednesday, March 1st. Robert W. Baird raised shares of Allogene Therapeutics from a “neutral” rating to an “outperform” rating and set a $12.00 price target for the company in a research note on Friday, January 6th. They noted that the move was a valuation call. Royal Bank of Canada dropped their price objective on Allogene Therapeutics from $32.00 to $22.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 1st. Finally, EF Hutton Acquisition Co. I reaffirmed a “buy” rating and set a $15.00 target price on shares of Allogene Therapeutics in a research report on Wednesday, March 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.67.
Allogene Therapeutics Stock Down 2.7 %
Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last issued its quarterly earnings results on Tuesday, February 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.05. The business had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.06 million. Allogene Therapeutics had a negative return on equity of 43.44% and a negative net margin of 136,885.59%. The business’s quarterly revenue was down 6.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.54) earnings per share. As a group, equities research analysts forecast that Allogene Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.
Allogene Therapeutics Profile
Allogene Therapeutics, Inc operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.
- Get a free copy of the StockNews.com research report on Allogene Therapeutics (ALLO)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.